JPS63502716A - - Google Patents

Info

Publication number
JPS63502716A
JPS63502716A JP50174686A JP50174686A JPS63502716A JP S63502716 A JPS63502716 A JP S63502716A JP 50174686 A JP50174686 A JP 50174686A JP 50174686 A JP50174686 A JP 50174686A JP S63502716 A JPS63502716 A JP S63502716A
Authority
JP
Grant status
Application
Patent type
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50174686A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
JP50174686A 1986-03-07 1986-03-07 Pending JPS63502716A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US1986/000495 WO1987005330A1 (en) 1986-03-07 1986-03-07 Method for enhancing glycoprotein stability

Publications (1)

Publication Number Publication Date
JPS63502716A true true JPS63502716A (en) 1988-10-13

Family

ID=22195409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50174686A Pending JPS63502716A (en) 1986-03-07 1986-03-07

Country Status (4)

Country Link
EP (1) EP0272253A4 (en)
JP (1) JPS63502716A (en)
DK (1) DK583087D0 (en)
WO (1) WO1987005330A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158763B2 (en) 2002-12-24 2012-04-17 Yasuhiro Kajihara Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain and processes for producing these

Families Citing this family (373)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007641A1 (en) * 1988-02-10 1989-08-24 Genzyme Corporation Enhancement of the therapeutic properties of glycoprotein
DE3927801A1 (en) * 1989-08-23 1991-02-28 Hoechst Ag Method for the enzymatic synthesis of galactosylated glycoprotein blocks
EP0642526B1 (en) 1991-10-15 1998-12-23 The Scripps Research Institute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of gdp-fucose
US6319695B1 (en) * 1991-10-15 2001-11-20 The Scripps Research Insitute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (en) * 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
EP1980618A2 (en) 1995-02-24 2008-10-15 Genentech, Inc. Human DNASE I variants
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
EP1500702A1 (en) 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
EP0942992B1 (en) 1997-01-31 2007-03-07 Genentech, Inc. O-fucosyltransferase
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
JP2001523977A (en) 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Apaf-1, ced-4 human homolog, activators of caspase-3
EP1032661A1 (en) 1997-06-18 2000-09-06 Genentech, Inc. Apo-2DcR
CA2309358A1 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
CA2382409A1 (en) 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE69839401T2 (en) 1997-09-18 2009-05-07 Genentech Inc., San Francisco DcR3 polypeptide, a TNFR homolog
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2001522584A (en) 1997-10-10 2001-11-20 ジェネンテク・インコーポレイテッド Apo-3 ligand polypeptide
EP2014770A3 (en) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
EP2033970A3 (en) 1997-10-29 2009-06-17 Genentech, Inc. Polypeptides and nucleic acids encoding the same
ES2316182T3 (en) 1998-01-15 2009-04-01 Genentech, Inc. Apo-2 ligand.
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
WO1999047677A3 (en) 1998-03-17 1999-11-11 Genentech Inc Polypeptides homologous to vegf and bmp1
ES2292242T5 (en) 1998-05-15 2011-05-04 Genentech, Inc. therapeutic uses homolog polypeptides IL-17.
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1956030B1 (en) 1999-06-15 2009-11-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
WO2001040466A3 (en) 1999-12-01 2002-05-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2319929A1 (en) 1998-12-23 2011-05-11 Genentech, Inc. IL-1 related polypeptides
EP2258848B1 (en) 1999-12-23 2014-03-05 Genentech, Inc. Il-17 homologous polypeptide and therapeutic uses thereof
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2327606T3 (en) 2000-01-10 2009-11-02 Maxygen Holdings Ltd GCSF conjugates.
KR20080006002A (en) 2000-01-13 2008-01-15 제넨테크, 인크. Novel stra6 polypeptides
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6576452B1 (en) 2000-10-04 2003-06-10 Genencor International, Inc. 2,5-diketo-L-gluconic acid reductases and methods of use
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20030232334A1 (en) 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
CA2469846A1 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
KR100607612B1 (en) 2001-06-20 2006-08-02 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
WO2003020892A3 (en) 2001-08-29 2004-02-26 Genentech Inc Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
EP2143437B1 (en) 2001-09-18 2013-08-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
DK2279755T3 (en) 2001-10-10 2014-05-26 Ratiopharm Gmbh Glycokonjugering of remodeling and fibroblast growth factor (FGF)
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7416858B2 (en) * 2001-10-10 2008-08-26 Neose Technologies, Inc. Pharmaceutical compositions of glycoconjugates
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1592708A2 (en) 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
WO2003046150A3 (en) 2001-11-28 2003-11-27 Neose Technologies Inc Glycoprotein remodeling using endoglycanases
WO2003057160A8 (en) 2002-01-02 2005-07-21 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
KR20040096592A (en) 2002-02-21 2004-11-16 와이어쓰 Follistatin domain containing proteins
JP2005535290A (en) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッドGenentech,Inc. Compositions and methods for the treatment of immune-related diseases
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
EP1501855A4 (en) 2002-03-21 2006-02-22 Sagres Discovery Inc Novel compositions and methods in cancer
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
CA2486252C (en) 2002-06-07 2012-07-24 Genentech, Inc. Methods for screening for agents that modulate hepatocellular carcinoma development
EP2383278A1 (en) 2002-07-08 2011-11-02 Genentech, Inc. Method to determine B cell mediated diseases
CN1735687A (en) 2002-08-02 2006-02-15 惠氏公司 MK2 interacting proteins
DK1546316T3 (en) 2002-08-12 2011-02-14 Danisco Us Inc Mutant E. coli AppA phytase enzymes and natural variants thereof nucleic acids encoding such phytase enzymes, vectors and host cells incorporating same and methods of making and using these
US20060199181A1 (en) 2002-09-11 2006-09-07 Genentch, Inc. Compositions and methods for the treatment of immune related diseases
CA2498008C (en) 2002-09-11 2014-02-04 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004028479A9 (en) 2002-09-25 2009-04-23 Genentech Inc Nouvelles compositions et methodes de traitement du psoriasis
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1581169A4 (en) 2002-11-08 2008-09-17 Genentech Inc Compositions and methods for the treatment of natural killer cell related diseases
EP2308968A1 (en) 2002-11-26 2011-04-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
FR2851471B1 (en) * 2003-02-24 2006-07-28 Synt Em Compounds comprising at least one active substance and at least one vector subsequently assembled by a bonding agent, their uses and said binding agents
US7632810B2 (en) 2003-03-12 2009-12-15 Genentech, Inc. Compositions with hematopoietic and immune activity
ES2420581T3 (en) 2003-03-14 2013-08-26 Biogenerix Gmbh water soluble polymers branched and their conjugates
EP2184298A1 (en) 2003-03-14 2010-05-12 Wyeth a Corporation of the State of Delaware Antibodies against human IL-21 receptor and uses therefor
WO2004087756A3 (en) 2003-04-02 2005-01-06 Hoffmann La Roche Antibodies against insulin-like growth factor i receptor and uses thereof
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2004103275A3 (en) 2003-05-09 2007-05-18 Neose Technologies Inc Compositions and methods for the preparation of human growth hormone glycosylation mutants
EP2248829A1 (en) 2003-05-30 2010-11-10 Genentech, Inc. Treatment with anti-VEGF antibodies
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
CA2530284A1 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005019258A3 (en) 2003-08-11 2006-04-13 Genentech Inc Compositions and methods for the treatment of immune related diseases
EP2327723A3 (en) 2003-10-10 2012-06-27 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP2412725A3 (en) 2003-11-17 2012-04-25 Genentech, Inc. Antibodies against CD79b for the treatment of tumor of hematopoeitic origin
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
CA2547140A1 (en) 2003-11-24 2005-06-09 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20090324604A1 (en) 2004-01-07 2009-12-31 Chiron Corporation M-csf specific monoclonal antibody and uses thereof
KR101439880B1 (en) 2004-01-08 2014-09-12 라티오팜 게엠베하 O-linked glycosylation of peptides
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
DE602005019038D1 (en) 2004-05-04 2010-03-11 Novo Nordisk Healthcare Ag O-linked glycoforms of factor VII and processes for their preparation
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US7740846B2 (en) 2004-07-20 2010-06-22 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
ES2551852T3 (en) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Receptor ActRII Polypeptides
WO2006031811A3 (en) 2004-09-10 2006-09-21 Henrik Clausen Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2589374C (en) 2004-11-30 2016-05-03 Curagen Corporation Antibodies directed to gpnmb and uses thereof
EP2548575A1 (en) 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
US9820986B2 (en) 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
US7615216B2 (en) 2005-04-01 2009-11-10 Roche Palo Alto Llc Antibodies against CCR5 and uses thereof
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5047947B2 (en) 2005-05-05 2012-10-10 デューク ユニバーシティ Anti-cd19 antibody treatment for autoimmune disease
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー/エス Glycopegylated first ix factor
CN102441163A (en) 2005-05-27 2012-05-09 比奥根艾迪克Ma公司 Tweak binding antibodies
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
JP2008541781A (en) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッドGenentech,Inc. Their use for the characterization of transgenic animals, and genes for different genes
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
ES2357626T3 (en) 2005-08-24 2011-04-28 The Rockefeller University Lysines mutants PLY-GBS.
WO2007056191A3 (en) 2005-11-03 2007-10-25 Neose Technologies Inc Nucleotide sugar purification using membranes
WO2007056858A1 (en) 2005-11-18 2007-05-24 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
CN105001320A (en) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa antagonists and uses for promoting bone growth
JP2009527227A (en) 2006-02-17 2009-07-30 ジェネンテック・インコーポレーテッドGenentech,Inc. Gene disruption, compositions and methods related thereto
US7901684B2 (en) 2006-02-21 2011-03-08 Wyeth Llc Antibodies against human IL-22 and uses therefor
US7811567B2 (en) 2006-02-21 2010-10-12 Wyeth Llc Methods of using antibodies against human IL-22
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008036437A3 (en) 2006-04-19 2008-10-02 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2420252A1 (en) 2006-08-04 2012-02-22 Novartis AG EPHB3-specific antibody and uses thereof
KR101433544B1 (en) 2006-08-18 2014-08-27 노바르티스 아게 Prlr-specific antibody and uses thereof
EP2752423A3 (en) 2006-09-18 2015-02-18 Compugen Ltd. GPCR ligands and method of using same
CA2664752A1 (en) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Antibodies against ccr5 and uses thereof
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As Methods for the purification of polypeptide conjugates
DK2068907T3 (en) 2006-10-04 2018-01-15 Novo Nordisk As Glycerol-bound pegylated sugars and glycopeptides
JP5519287B2 (en) 2006-11-02 2014-06-11 ダニエル・ジェイ・カポン Hybrid immunoglobulin having a movable portion
KR20170012582A (en) 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Alk1 receptor and ligand antagonists and uses thereof
US8377439B2 (en) 2006-12-07 2013-02-19 Novartis Ag Antagonist antibodies against EPHB3
KR20170130620A (en) 2007-02-02 2017-11-28 악셀레론 파마 인코포레이티드 Variants derived from actriib and uses therefor
US8173601B2 (en) 2007-02-09 2012-05-08 Acceleron Pharma, Inc. Activin-ActRIIa antagonists and uses for treating multiple myeloma
US7875431B2 (en) 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CN101861168B (en) 2007-05-07 2014-07-02 米迪缪尼有限公司 Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2551123T3 (en) 2007-06-12 2015-11-16 Ratiopharm Gmbh Improved process for the production of nucleotide sugars
CA2693651A1 (en) 2007-07-12 2009-01-15 Ronen Shemesh Bioactive peptides and method of using same
CN101981055B (en) 2008-01-31 2016-03-09 健泰科生物技术公司 Anti cd79b antibodies and immunoconjugates and methods of use
ES2528922T3 (en) 2007-07-16 2015-02-13 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CA2693255A1 (en) 2007-07-16 2009-01-22 Yvonne Chen Anti-cd79b antibodies and immunoconjugates and methods of use
EP2188313B1 (en) 2007-08-21 2017-11-01 Amgen, Inc. Human c-fms antigen binding proteins
KR101599704B1 (en) 2007-08-29 2016-03-07 사노피 Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
EP2769728A1 (en) 2007-09-04 2014-08-27 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US8268311B2 (en) 2007-09-18 2012-09-18 Amgen Inc. Human GM-CSF antigen binding proteins
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
CA2703997C (en) 2007-12-26 2017-04-04 Xencor, Inc. Fc variants with altered binding to fcrn
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
ES2618292T3 (en) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Human CD39 antibodies and their use to inhibit the activity of regulatory T cells
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2294087B1 (en) 2008-05-01 2014-05-14 Amgen, Inc. Anti-hepcidin antibodies and methods of use
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
CA2727161A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
ES2558842T3 (en) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation based mixed GIP for the treatment of metabolic disorders and obesity agonists
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2340031A4 (en) 2008-08-14 2013-01-09 Acceleron Pharma Inc Use of gdf traps to increase red blood cell levels
RU2592670C2 (en) 2009-08-13 2016-07-27 Акселерон Фарма Инк. Combined application of traps of gdf and erythropoietin receptor activators for increasing erythrocyte content
KR101432474B1 (en) 2008-09-07 2014-08-21 글라이코넥스 인코포레이티드 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
CA2742899A1 (en) 2008-11-06 2010-05-14 Glenmark Pharmaceuticals, S.A. Treatment with anti-alpha2 integrin antibodies
JP5933975B2 (en) 2008-11-12 2016-06-15 メディミューン,エルエルシー Antibody preparation
CN102300874B (en) 2008-12-08 2015-08-05 卡姆普根有限公司 Tmem154 polypeptides and polynucleotides and their use as pharmaceutical and biological products to produce a target for drug
CN102245624B (en) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 Based on insulin prodrug amide
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
CN102348722B (en) 2008-12-23 2016-06-08 安姆根有限公司 Receptor binding protein human cgrp
CA2752647A1 (en) 2009-02-24 2010-09-02 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
US20120064096A1 (en) 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US8563513B2 (en) 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
JP5755635B2 (en) 2009-03-30 2015-07-29 アクセルロン ファーマ, インコーポレイテッド Bmp-alk3 its use for the antagonists and bone growth promoting
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
US8580732B2 (en) 2009-04-07 2013-11-12 Duke University Peptide therapy for hyperglycemia
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
EP3290439A1 (en) 2009-06-12 2018-03-07 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP3202459A1 (en) 2009-09-09 2017-08-09 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for regulating body fat content
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2488552A1 (en) 2009-10-12 2012-08-22 Amgen Inc. Use of il-17 receptor a antigen binding proteins
CA2777717A1 (en) 2009-10-15 2011-04-21 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
KR101568461B1 (en) 2009-10-26 2015-11-12 암젠 인크 Human il-23 antigen binding proteins
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
EP3260130A3 (en) 2009-11-03 2018-02-07 Acceleron Pharma Inc. Methods for treating fatty liver disease
JP6267425B2 (en) 2009-11-17 2018-01-24 アクセルロン ファーマ, インコーポレイテッド actriib proteins and variants and their use thereof relates utrophin induction for muscular dystrophy treatment
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
WO2011066503A3 (en) 2009-11-30 2011-10-27 Genentech, Inc. Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
EP2507265B1 (en) 2009-12-01 2016-05-11 Compugen Ltd. Antibody specific for heparanase splice variant T5 and its use.
JP2013512674A (en) 2009-12-02 2013-04-18 アクセルロン ファーマ, インコーポレイテッド Compositions and methods for increasing the serum half-life of the Fc fusion protein
EP3202787A1 (en) 2009-12-07 2017-08-09 Amgen, Inc Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
RU2012136450A (en) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Conjugates glucagon antagonist - agonist gip and compositions for treating metabolic disorders and obesity
WO2011097527A3 (en) 2010-02-04 2012-01-26 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
RU2595389C2 (en) 2010-02-23 2016-08-27 Дженентек, Инк. Compositions and methods for diagnosing and treating cancer
JP5972176B2 (en) 2010-02-23 2016-08-17 サノフイ Anti-alpha 2 integrin antibodies and their use
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
CN107090045A (en) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 Compositions and methods for the diagnosis and treatment of tumor
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
ES2661228T3 (en) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Peptides glucagon superfamily receptor activity showing nuclear hormone
WO2011160062A3 (en) 2010-06-17 2012-03-15 Actogenix Nv Compositions and methods for treating inflammatory conditions
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
WO2011163012A3 (en) 2010-06-24 2013-07-11 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CA2805024A1 (en) 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiples sclerosis, rheumatoid arthritis and other autoimmune disorders
EP2596025B1 (en) 2010-07-23 2018-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
JP5953303B2 (en) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド Antibodies having isoelectric points that have been modified
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP2725034A1 (en) 2010-09-22 2014-04-30 Amgen Inc. Carrier immunoglobulins and uses thereof
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
RU2607452C2 (en) * 2010-11-04 2017-01-10 Академиа Синика Methods of producing viral particles with simplified surface proteins' glycosylation
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
US20130273062A1 (en) 2010-12-22 2013-10-17 Orega Biotech Antibodies against human cd39 and use thereof
JP6086067B2 (en) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon analogues showing the Gip receptor activity
WO2012090150A3 (en) 2010-12-27 2012-11-01 Compugen Ltd New cell-penetrating peptides and uses thereof
EP2658870B1 (en) 2010-12-30 2018-04-25 Takeda Pharmaceutical Company Limited Conjugated anti-cd38 antibodies
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
KR20140033037A (en) 2011-03-31 2014-03-17 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Antibodies directed against icos and uses thereof
CN103596974B (en) 2011-04-15 2016-08-31 卡姆普根有限公司 Polypeptides and polynucleotides, and uses for treating immune-related disorders and cancer
US9932386B2 (en) 2011-04-20 2018-04-03 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
KR20140041572A (en) 2011-05-19 2014-04-04 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Anti-human-her3 antibodies and uses thereof
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
KR20140043792A (en) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
CA2836855A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
WO2013043933A3 (en) 2011-09-22 2013-05-30 Amgen Inc. Cd27l antigen binding proteins
WO2013052933A3 (en) 2011-10-06 2013-09-12 The Board Of Trustees Of The University Of Illinois Myosin binding protein- c for use in methods relating to diastolic heart failure
JP6310394B2 (en) 2011-10-10 2018-04-11 ゼンコア インコーポレイテッド Method of purifying the antibody
RU2014117678A (en) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon superfamily peptides having glucocorticoid receptor activity
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
US20150045301A1 (en) 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
KR20140126357A (en) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 antibodies, and uses thereof for treatment of cancer
KR20140123558A (en) 2012-02-02 2014-10-22 악셀레론 파마 인코포레이티드 Alk1 antagonists and their uses in treating renal cell carcinoma
CN104394880A (en) 2012-03-16 2015-03-04 大学保健网络 Methods and compositions for modulating toso activity
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013163377A1 (en) 2012-04-27 2013-10-31 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
EP2861259A1 (en) 2012-06-14 2015-04-22 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
CN104583233A (en) 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Analogs of glucagon exhibiting GIP receptor activity
KR20150023013A (en) 2012-06-21 2015-03-04 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon analogs exhibiting gip receptor activity
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
CN104918958A (en) 2012-11-20 2015-09-16 赛诺菲 Anti-CEACAM5 antibodies and uses thereof
US20150344583A1 (en) 2012-12-07 2015-12-03 Amgen Inc. Bcma antigen binding proteins
CN105452295A (en) 2012-12-10 2016-03-30 比奥根Ma公司 Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2014102299A3 (en) 2012-12-27 2014-10-02 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
EP2943511A4 (en) 2013-01-14 2016-08-31 Xencor Inc Novel heterodimeric proteins
KR20150129685A (en) 2013-03-15 2015-11-20 젠코어 인코포레이티드 Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2948478A1 (en) 2013-01-25 2015-12-02 Amgen Inc. Antibodies targeting cdh19 for melanoma
US20140322218A1 (en) 2013-01-25 2014-10-30 Amgen Research (Munich) Gmbh Antibody Constructs for CDH19 and CD3
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US20140271629A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
DK2970422T3 (en) 2013-03-15 2018-07-16 F Hoffmann La Roche Ag IL-22 polypeptides and IL-22 Fc fusion proteins and methods of using
RU2015144105A (en) 2013-03-15 2017-04-24 ИНТРИНСИК ЛАЙФСАЙЕНСИС, ЭлЭлСи Antibodies to hepcidin and their applications
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
WO2014144632A8 (en) 2013-03-15 2015-12-30 Amgen Inc. Human pac1 antibodies
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
KR20150128796A (en) 2013-03-15 2015-11-18 바이오젠 엠에이 인코포레이티드 Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
WO2014143739A3 (en) 2013-03-15 2014-11-06 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP3036320A1 (en) 2013-08-19 2016-06-29 Biogen MA Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
CA2922808A1 (en) 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
US20160317657A1 (en) 2013-09-13 2016-11-03 Amgen Inc. Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia
WO2015052537A1 (en) 2013-10-11 2015-04-16 Oxford Biotherapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
WO2015066557A1 (en) 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease molecules with altered glycosylation and methods
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
WO2015127134A3 (en) 2014-02-20 2015-11-05 Allergan, Inc. Complement component c5 antibodies
KR20160126054A (en) 2014-02-27 2016-11-01 알러간, 인코포레이티드 COMPLEMENT FACTOR Bb ANTIBODIES
CN106471009A (en) 2014-03-28 2017-03-01 Xencor公司 Bispecific antibodies that bind to CD38 and CD3
US20170037148A1 (en) 2014-04-16 2017-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
FR3020063A1 (en) 2014-04-16 2015-10-23 Gamamabs Pharma anti-human antibody HER4
JP2017526350A (en) 2014-07-31 2017-09-14 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Optimal among of species specific bispecific single chain antibody construct
EP3174903A1 (en) 2014-07-31 2017-06-07 Amgen Research (Munich) GmbH Bispecific single chain antibody construct with enhanced tissue distribution
EP3186279A1 (en) 2014-07-31 2017-07-05 Amgen Research (Munich) GmbH Antibody constructs for cdh19 and cd3
WO2016040767A3 (en) 2014-09-12 2016-04-28 Amgen Inc. Chrdl-1 epitopes and antibodies
CN108064248A (en) 2014-09-30 2018-05-22 生物控股有限公司 Human anti dipeptide repeat (DPR) antibody
US20170327861A1 (en) 2014-10-17 2017-11-16 Biogen Ma Inc. Copper Supplementation for Control of Glycosylation in Mammalian Cell Culture Process
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
US20170327786A1 (en) 2014-10-31 2017-11-16 Biogen Ma Inc. Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
WO2016086189A3 (en) 2014-11-26 2016-09-09 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US20160355608A1 (en) 2014-11-26 2016-12-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
US20170037131A1 (en) 2015-03-05 2017-02-09 Matthew Bernett Modulation of t cells with bispecific antibodies and fc fusions
CN108136001A (en) 2015-04-03 2018-06-08 佐马技术有限公司 Using TGF-β inhibitors and PD-1 inhibitors for the treatment of cancer
JP2018512151A (en) 2016-05-04 2018-05-17 アムジエン・インコーポレーテツド Interleukin-2 mutein for the proliferation of regulatory t cells
JP2018512860A (en) 2015-04-17 2018-05-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Bispecific antibody constructs against Cdh3 and cd3
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
EP3322733A1 (en) 2015-07-13 2018-05-23 Compugen Ltd. Hide1 compositions and methods
WO2017021354A1 (en) 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Antibody constructs for cd70 and cd3
EP3328891A1 (en) 2015-07-31 2018-06-06 Amgen Research (Munich) GmbH Antibody constructs for flt3 and cd3
US20170029502A1 (en) 2015-07-31 2017-02-02 Amgen Research (Munich) Gmbh Antibody constructs for msln and cd3
US20170029512A1 (en) 2015-07-31 2017-02-02 Amgen Research (Munich) Antibody constructs for egfrviii and cd3
WO2017021349A1 (en) 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Bispecific antibody constructs binding dll3 and cd3
WO2017066561A3 (en) 2015-10-16 2017-06-08 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017129585A1 (en) 2016-01-25 2017-08-03 Amgen Research (Munich) Gmbh Pharmaceutical composition comprising bispecific antibody constructs
WO2017182427A1 (en) 2016-04-19 2017-10-26 Amgen Research (Munich) Gmbh Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
WO2018005954A3 (en) 2016-07-01 2018-03-29 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
WO2018013917A1 (en) 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2018015340A1 (en) 2016-07-18 2018-01-25 Sanofi Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
WO2018064255A3 (en) 2016-09-28 2018-06-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
WO2018064098A1 (en) 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides
US20180127487A1 (en) 2016-10-20 2018-05-10 Sanofi Anti-chikv antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847890A (en) * 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY=1977 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158763B2 (en) 2002-12-24 2012-04-17 Yasuhiro Kajihara Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain and processes for producing these

Also Published As

Publication number Publication date Type
WO1987005330A1 (en) 1987-09-11 application
DK583087A (en) 1987-11-06 application
EP0272253A1 (en) 1988-06-29 application
EP0272253A4 (en) 1990-02-05 application
DK583087D0 (en) 1987-11-06 grant

Similar Documents

Publication Publication Date Title
JPH0226900Y2 (en)
DE8604919U1 (en)
DE8621253U1 (en)
JPH0129639B2 (en)
DE8629983U1 (en)
DE8601335U1 (en)
JPH0124109Y2 (en)
DE8629417U1 (en)
DE8608975U1 (en)
DE8702754U1 (en)
JPH0133186B2 (en)
DE8618917U1 (en)
DE8623325U1 (en)
DE8609102U1 (en)
DE8614956U1 (en)
JPH0248045Y2 (en)
DE8627061U1 (en)
DE8628091U1 (en)
DE8623804U1 (en)
DE8631912U1 (en)
DE8701055U1 (en)
JPH0242483Y2 (en)
DE8616879U1 (en)
JPH0239549Y2 (en)
JPH01502727A (en)